An outpatient psychiatric evaluation is conducted for a male patient of African descent re… — USMLE Step 3

An outpatient psychiatric evaluation is conducted for a male patient of African descent regarding his ongoing management of treatment-resistant schizophrenia. The patient initiated clozapine therapy four weeks ago. Prior to starting the medication, hematologic assessment revealed an absolute neutrophil count (ANC) of $1,200/\text{mm}^3$ . Consequently, a hematologist documented a diagnosis of benign ethnic neutropenia (BEN) within the Clozapine Risk Evaluation and Mitigation Strategy (REMS) registry. The patient currently reports an excellent clinical response with no residual auditory hallucinations. He is afebrile and lacks any signs of infection. Laboratory analysis today demonstrates a total leukocyte count of $3,100/\text{mm}^3$ and an ANC of $850/\text{mm}^3$ . Based on the Clozapine REMS parameters specific to this patient's documented diagnosis, which of the following represents the most appropriate next step in management?

A
Interrupt clozapine therapy and monitor the absolute neutrophil count daily
B
Continue clozapine at the current dose and maintain weekly absolute neutrophil count monitoring
Continue clozapine at the current dose and monitor the absolute neutrophil count three times weeklyAnswer
D
Permanently discontinue clozapine and transition to a different atypical antipsychotic
E
Interrupt clozapine therapy and administer filgrastim

Answer

Continue clozapine at the current dose and monitor the absolute neutrophil count three times weekly

The correct answer involves continuing clozapine and increasing the monitoring frequency to three times weekly. Under the Clozapine Risk Evaluation and Mitigation Strategy (REMS), the monitoring algorithms differ significantly for patients with documented benign ethnic neutropenia (BEN). For the standard population, an absolute neutrophil count (ANC) between

500/\text{mm}^3

and

999/\text{mm}^3

is considered moderate neutropenia and mandates interrupting therapy with daily monitoring. However, patients with BEN naturally reside at lower ANC baselines without an increased risk of severe infections. Therefore, for BEN patients, an ANC in the

500-999/\text{mm}^3

range permits the continuation of clozapine, provided that monitoring is increased to three times weekly until the ANC reaches

\ge 1,000/\text{mm}^3

or returns to the patient's baseline.

Step-by-Step Solution

Identify the patient's baseline diagnosis and current laboratory findings.

The patient has a documented diagnosis of benign ethnic neutropenia (BEN) and presents with a current ANC of

850/\text{mm}^3

Monitoring parameters for clozapine are specifically tailored based on the presence or absence of BEN.

Determine the appropriate Clozapine REMS algorithm to apply.

Because the patient is registered with BEN, the BEN-specific monitoring thresholds must be utilized rather than the standard population thresholds.

Applying standard thresholds to BEN patients leads to the unnecessary interruption of effective psychiatric therapy.

Correlate the ANC with the BEN-specific REMS guidelines to determine the next management step.

For a BEN patient with an ANC between

500

and

999/\text{mm}^3

, the correct action is to continue therapy and increase monitoring to three times weekly.

This ensures close clinical and laboratory surveillance while avoiding premature discontinuation in a patient whose baseline ANC is naturally lower.

Key Concept

Clozapine REMS monitoring for Benign Ethnic Neutropenia

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic